lapatinib has been researched along with 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene in 1 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene) | Trials (14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene) | Recent Studies (post-2010) (14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 25 | 1 | 25 |
| Protein | Taxonomy | lapatinib (IC50) | 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | 0.0972 | |
| Cyclin-K | Homo sapiens (human) | 0.003 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.007 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.009 | |
| Cyclin-A2 | Homo sapiens (human) | 0.013 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.006 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0282 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.0397 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 0.0257 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0027 | |
| Cyclin-H | Homo sapiens (human) | 0.02 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 0.02 | |
| Cyclin-A1 | Homo sapiens (human) | 0.013 | |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | 0.0063 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.0037 | |
| Platelet-activating factor acetylhydrolase | Homo sapiens (human) | 0.073 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.004 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
1 other study(ies) available for lapatinib and 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene
| Article | Year |
|---|---|
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |